

ACT-Accelerator – Plan, Investment Case, & Advocacy Campaign

Civil Society & Community Organization Briefing


29 September 2020

Goals

- **Sharing the ACT-Accelerator Story:** from start-up to scale-up
- **Understanding the Investment Case:** & financing requirements
- **Joining the ACT-A Advocacy Campaign:** financing ACT-A
- **Supporting CSOs:** how can we take advocacy forward together?

The ACT-Accelerator Plan & Investment Case

Released 25 September 2020




Status Report & Plan provides an overview of ACT-Accelerator's goal, approach, achievements to date & near-term priorities.

Investment Case provides an economic rationale for investing in ACT-A as a global, integrated, 'end-to-end' solution.




Developed collectively by Partners in consultation with the Facilitation Council

ACT-A goal: accelerated global access to tools that rapidly reduce risk of severe disease & end acute phase of pandemic




ACT-A's critical path uses accelerated & parallel workstreams to rapidly achieve its goal



ACT-A is a bold structure, driving **unprecedented collaboration**

Deep engagement of Principals, integrated workplans & budgets, working with the entire development system





ACT-A is the most effective investment to address COVID-19 & its consequences

Comprehensive public health tool box

ACT-A is the only mechanism with Vaccines, Therapeutics, Diagnostics, PPE and O2, the full spectrum of products needed to beat the pandemic

Reduces R&D risks

ACT-A has the largest and most diverse R&D portfolio in the world

Mitigates operational risks

ACT-A co-conveners are the experts in implementing global public health

Unique global reach

ACT-A, by design, is the only mechanism that looks after all the people at the same time

Some key landmarks from the start-up phase

- **Diagnostics:** new Ag RDTs, with EULs & volume/price guarantees
- **Vaccines:** COVAX Facility in business (167 countries & growing)
- **Allocation:** WHO Framework is the emerging standard
- **Therapeutics:** Dexamethasone now in rollout

Concrete outcomes of the ACT-Accelerator Collaboration

Immediate priorities for Oct – Dec 2020



R&D



Manufacturing



Procurement



Delivery



Vaccines

Add **1-5 candidates to portfolio** based on imminent readouts

Negotiate new deals with manufacturers based on **imminent Phase II/II results**

Step up country preparedness efforts to deploy as soon as possible



Therapeutics

Evaluate new monoclonal antibodies and antivirals

Select molecules for **1st wave of manufacturing capacity reservations**

Launch 3-5 further **market interventions for repurposed medicines**

Scale up Dexamethasone



Diagnostics

Accelerate evaluation of novel diagnostics

Rollout 10s of millions of antigen-detecting **RDTs**

Pre-empt deployment needs for antigen-detecting **RDTs**



Access & Allocation

Cross-cutting priorities detailed in Plan

Health Systems Connector





BUT...ACT-A needs 2 major step changes in this crucial period

Step change in financing to scale up for impact, \$ B rounded



New level of coordination for roll out of scarce vaccines Vaccine doses secured¹, M doses by 2021




Understanding the ACT-A Investment Case & Financing Needs

The economic argument | unprecedented domestic stimulus has helped hedge the crisis but only in some sectors & countries


\$US 10 trillion in stimulus unlocked by G20 countries to support businesses & economies

Size of stimulus package – in \$B




Economic support is already showing mixed outlook

Financial indices – 100=1 Jan-20, as of 31 August 2020




EU unemployment rate – in % population¹



¹ Source: OECD Data


Sectors that depend heavily on international trade & mobility will not recover with existing government stimulus



¹ pre-COVID GDP at end of 2021 expected to be \$US 152 trillion worldwide. In April, forecasts post-COVID predicted \$US 138 trillion. The loss for G20 economies would be ~\$US 10 - 13 trillion, IMF, World Bank; ² 2020 Travel & Tourism drop by \$US 3.7 trillion, WTTC; ³ International trade is facing contraction that could reach -32%; IMF, WTO, BCG analysis; ⁴. \$US 3 trillion excluding China. Source: World Bank, WTO, BCG analysis.

Rapidly reducing severe COVID-19 disease in LIC/LMICs would save lives and fully restore international mobility & trade and long term growth

Equitable access to COVID-19 tools will allow LIC/LMIC domestic economies to recover...





...restoring international mobility & trade and delivering short term value and long term growth to HICs.¹

■ Significant investments ■ Limited investments


¹ Emerging markets are contributing to 74% of 2020 GDP growth and 30% of international trade; source: WTO, IMF

Financing Requirements & Economic Rationale: the \$US35 Bn is paid back in 36 hours, once int'l mobility & trade is restored



1. Additional critical funding required by end of 2020 to meet ACT-Accelerator targets (excl. proportion already funded); 2. As of 7 September 2020; 3. Assuming 25% of total ask in 2020

Evolving arc of the ACT-Accelerator Advocacy Campaign




1st Council: Final Outcome Statement & Next Steps

'We will

- *provide sustained political leadership...*
- *advocate for the ACT-A Investment Case...*
- *honour our shared commitment to leave no-one behind...'*

Next steps: planning meetings with Co-Chairs on week basis



ACT-A at UNGA: 30 September 2020



Accelerating the end of the COVID-19 pandemic:
taking new solutions to scale and making them equitably accessible, to save lives, protect health systems and restart the global economy

Concept: high-level side event on the ACT-Accelerator at the 75th session of UNGA

30 September, 8:30-10:00am EST

Objectives
The overarching objectives of this event are to:

- build stronger political consensus for a coordinated global response to COVID-19 and champion the importance and urgency of equitable access to new tools, especially effective vaccines
- catalyze a *step change* in support for the Access to COVID-19 Tools Accelerator (ACT-A), and its mechanisms like the COVAX Vaccines Facility, the most promising multilateral solutions for global equitable access to the tools needed to accelerate the end of the pandemic

Context
The UN has from the outset of the pandemic been calling for global solidarity to combat COVID-19. The already overwhelming burden on health systems, and social and economic consequences, could deteriorate further with subsequent waves of the disease that could prove especially challenging for vulnerable countries and populations.

Registration open at:

<https://access-for-all.world-television.com/register>

Advocacy Campaign: Financing the ACT-Accelerator

Global framing of the ACT-Accelerator Ask:


Beyond ODA to 1% of Fiscal Stimulus*

- The lack of an adequately financed global exit strategy is an **existential threat to the economic and health security of all** nations and citizens
- **Only by tackling the causes of the pandemic, globally,** will economic vitality be restored at home & catastrophe in poorest countries be averted
- ACT-A is **the only comprehensive investment approach** that can address the root cause of the COVID-19 crisis & accelerate the end of the pandemic
- **G20/OECD countries are called upon to contribute 1% of domestic stimulus spending, or the equivalent amount, to the global COVID-19 response, with the first funds going to fully funding the ACT-Accelerator**

* To be adapted in individual markets depending on context

Unpacking the numbers: how might the \$38 billion ACT-Accelerator budget be funded?

NOTE: it is expected that MDBs & IFIs will play a substantive role – to be included going forward




Underpinning assumptions

- ~10% of ACT-A budget could be funded by private sector & EC
- remaining funding needs covered primarily by G20/OECD
- a substantive proportion could be covered by concessional loans / domestic resources (TBD)

ANALYTIC: 1% fiscal stimulus for global response priority is 0.34% for a fully-funded ACT-A

Developing our G20 “asks” (in US \$B)

12 countries represent up to 90% of the G20 “ask”



This analytic is illustrative.

NEXT STEP: adapting & developing individual markets/contexts ‘asks’

. Source: IMF, World Bank; BCG analysis

Securing a fully-funded ACT-Accelerator will require extraordinary action by world leaders

- ACT-A is an integral part of economic stimulus & must be financed accordingly
- There is not \$35 Bn of funding (in next 6 months!) in ODA budgets
- Making ACT-A funding available requires an all-of-government approach (Head of Govt, Health, Finance, Treasury, Development, MoFA, Trade...)
- Ensuring ACT-A is fully financed is in countries' enlightened self-interest
- **Deep engagement by CSOs & Community Organizations will be critical**

Social Media pack ACT-Accelerator

Social media toolkit link



#ACTogether

#COVID19

Hashtag

#ACTogether
#COVID19

Channels

| Primary Account | Partner Accounts |
|--|--|
| <p>Twitter</p> <p>@WHO - World Health Organization</p> | <p>Twitter</p> <p>@O_Tulios - Director-General of the World Health Organization</p> <p>@UN - United Nations</p> <p>@EU_Commission - European Commission</p> <p>@Cgates - French Government</p> <p>@GovernmentZA - South African Government</p> <p>@GOV.UK - UK Government</p> <p>@GovI - GovI, the Vaccine Alliance</p> <p>@GlobalFund - The Global Fund</p> <p>@IMHaid - IMHaid</p> <p>@WorldBank - World Bank</p> <p>@WellcomeTrust - Wellcome</p> <p>@GatesFoundation - Gates Foundation</p> <p>@CEPIvaccines - CEPI</p> <p>@INDdx - FIND</p> |

| | |
|---|---|
| <p>The Access to #COVID19 Tools (ACT) Accelerator brings together governments, health organizations, scientists, businesses, civil society & philanthropists to speed up an end to the pandemic.</p> <p>More details ↗ bit.ly/2S0Lx8h</p> | <p>Download and insert the video: bit.ly/32YiaBw</p> |
| <p>(Your country or organization name) and over 170 countries are engaged in the new #COVID19 Vaccine Facility and 10 candidate vaccines are under evaluation - 9 of them in clinical trials, giving the largest and most diverse COVID-19 vaccine portfolio in the world.</p> <p>More details ↗ bit.ly/2S0Lx8h</p> |  <p>Download the image here</p> |
| <p>Our investment in the Access to #COVID19 Tools (ACT) Accelerator's multilateral approach will increase the chance of success for all countries by giving access to a greater number of tools more quickly, as well as sharing the costs, and mitigating the risks of R&D.</p> <p>More details ↗ bit.ly/2S0Lx8h</p> |  <p>Download the image here</p> |

© ACT Accelerator 2020

ACT Accelerator is a proven, up-and-running, COVID-19 exit strategy for the world & is already delivering returns.

ACT-A is the only mechanism explicitly designed to achieve:

- a simultaneous end to the pandemic everywhere,
- with a concomitant return to health, and
- a faster and more sustained return to global mobility, trade & economic activity

We are calling on leaders around the world to ACT NOW to change the course of the pandemic.

How can CSOs take forward ACT-A advocacy?

